Identification of potential metastasis associated miRNAs in colorectal cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA492457 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:To identify potential metastasis associated miRNAs in colorectal cancer (CRC), we performed miRNA array on normal mucosa, CRC tissues without metastasis and CRC tissues with distant metastasis.
2018-09-22 | GSE120300 | GEO
Project description:The purpose of this study is to identify miRNAs involved in the pathology of colorectal cancer (CRC) liver metastasis and investigate their underlying mechanisms. A total of 39 miRNAs were identified to be differentially expressed between 16 primary CRC tissues with liver metastases and 16 CRC tissues without liver metastases from 32 patients by Affymetric miRNA microarrays. 16 coloretcal cancer tissues with liver metastasis and 16 colorectal cancer tissues without liver metastasis were included in this study for RNA extraction and hybridization on Affymetrix microarrays. We sought to identify the differentially expressed miRNAs between colorectal cancer tissues with and without liver metastasis.
2013-12-10 | E-GEOD-53159 | biostudies-arrayexpress
Project description:Metastasis is a complex process involving multiple steps. We were interested in the role of microRNAs (miRNAs) in the process of liver colonization by colorectal cancer cells. We hypothesized that the comparison between non-metastatic versus metastatic isogenic cell line should thus offer valuable insight to the molecular mechanisms involved in developing metastatic behavior. KM12C/KM12SM and SW480/SW620 are probably the best available models of isogenic cell lines differing in metastatic properties for colorectal cancer. Our first goal was to identify miRNAs that contribute to the metastatic traits of the isogenic colorectal cancer cell lines, KM12C/KM12SM and SW480/SW620. Total RNA was extracted from cells using the mirVana kit (Ambion). Total RNA (1 µg) from KM12C and SW480 (poorly metastatic) and KM12SM and SW620 (highly metastatic) cells was used to analyze the global miRNA expression profiling with TaqMan Megaplex human array A (v2.0) and B (v3.0) (Applied Biosystems).
2017-03-01 | GSE86302 | GEO
Project description:Identification of circular RNA and miRNAs during colorectal cancer progression and metastasis
| PRJNA684603 | ENA
Project description:The purpose of this study is to identify miRNAs involved in the pathology of colorectal cancer (CRC) liver metastasis and investigate their underlying mechanisms. A total of 39 miRNAs were identified to be differentially expressed between 16 primary CRC tissues with liver metastases and 16 CRC tissues without liver metastases from 32 patients by Affymetric miRNA microarrays.
2013-12-10 | GSE53159 | GEO
Project description:miRNAs associated with breast cancer brain metastasis
| PRJNA896206 | ENA
Project description:The goal of this study is to determine the extracellular miRNAs associated with breast cancer metastasis to the brain. By combining the small RNA-seq data of patient sera and cell culture models, we are able to select breast cancer cell-derived miRNAs that are associated with brain metastasis for further functional study.
2023-11-01 | GSE216934 | GEO
Project description:Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. The roles of microRNAs (minRNAs) in mRNA destabilization and translational repression of this disease are well appreciated, their involvement in endonucleolytic cleavage of target mRNAs is poorly understood. Methods: Degradome sequencing was used to identify cleaved targets of some regulated miRNAs. Results: A sum of 9685 potential target genes were characterized for 268 conserved miRNAs and a total of 202 potential target genes were identified for 33 novel miRNAs by degradome sequencing. Target genes were further predicted to be involved in proteoglycans in cancer and AMPK signaling pathway. Five pairs of DEmiRNAs and directed target genes were randomly selected and their negative correlations were validated by RT-qPCR. Conclusions: A number of potential genes targeted by miRNAs were identified and endonucleolytic miRNA-directed mRNA cleavages occur in CRC. Our findings may lead to a better understanding of the novel role of miRNA in the gene regulation of CRC.
2020-03-02 | GSE125962 | GEO
Project description:A gene expression profiling suggested some gene candidates associated with colorectal cancer (CRC) metastasis, which were validated by qPCR investigation of the mRNA levels in clinical specimens Two-condition experiment, tumor tissue versus the adjacent non-tumor tissue. Biological replicates: 4
2010-10-16 | E-GEOD-24639 | biostudies-arrayexpress
Project description:Colorectal cancer (CRC) ranks as the third most prevalent cancer worldwide. Recent studies suggest the promising potential of microRNAs (miRNA) in predicting the status of circulating tumor cells (CTC), and their combined analyses could pave the way for significant advancements in assessing the risk of metastatic cancer. Here, we investigate the circulating miRNA signatures associated with CTC status in metastatic CRC (mCRC). The CTC status was assessed using AdnaTest ColonCancer technology, which detects tumor cells using an immunomagnetic approach and characterizes them based on colon-specific surface markers. The miRNA profiles were then analyzed using the Agilent miRNA microarray platform in 8 CTC-positive, 8 CTC-negative, and eight healthy individuals. The functional implications of dysregulated miRNAs and their interactions with target mRNAs, TFs, and lncRNAs were determined through a comprehensive in silico analysis. We identified two groups of downregulated miRNAs associated with CTC status/metastasis and multiple candidate biomarkers in suggested miRNA regulatory networks. Four miRNAs (miR-181c-5p, miR-199a-5p, miR-500b-5p, miR-769-5p) were prioritized as findings were consistent with their tissue expressions in TCGA datasets. Our findings reveal candidate biomarkers with potential for CTC status and mCRC-associated CTC detection, providing insights for new translational medicine applications in mCRC management.
2025-04-16 | GSE285322 | GEO